ProShare Advisors’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.19M Buy
37,088
+6,437
+21% +$564K ﹤0.01% 632
2026
Q1
$2.77M Sell
30,651
-7,630
-20% -$700K ﹤0.01% 655
2025
Q4
$3.44M Buy
38,281
+3,077
+9% +$292K 0.01% 629
2025
Q3
$3.47M Sell
35,204
-46
-0.1% -$4.56K 0.01% 623
2025
Q2
$3.22M Buy
35,250
+3,691
+12% +$357K 0.01% 627
2025
Q1
$3.57M Buy
31,559
+1,422
+5% +$152K 0.01% 579
2024
Q4
$3.18M Sell
30,137
-24,819
-45% -$2.66M 0.01% 599
2024
Q3
$5.93M Buy
54,956
+25,029
+84% +$2.73M 0.01% 484
2024
Q2
$3.25M Buy
29,927
+1,722
+6% +$203K 0.01% 586
2024
Q1
$3.72M Sell
28,205
-725
-3% -$90.6K 0.01% 548
2023
Q4
$3.52M Sell
28,930
-2,875
-9% -$321K 0.01% 548
2023
Q3
$3.57M Sell
31,805
-1,336
-4% -$170K 0.01% 538
2023
Q2
$4.83M Buy
33,141
+681
+2% +$92.5K 0.01% 504
2023
Q1
$4.19M Buy
32,460
+4,051
+14% +$509K 0.01% 513
2022
Q4
$3.62M Sell
28,409
-152
-0.5% -$17.6K 0.01% 507
2022
Q3
$2.99M Sell
28,561
-3,205
-10% -$352K 0.01% 537
2022
Q2
$3.34M Sell
31,766
-12,385
-28% -$1.47M 0.01% 561
2022
Q1
$5.65M Sell
44,151
-2,629
-6% -$317K 0.01% 526
2021
Q4
$5.77M Buy
46,780
+10,543
+29% +$1.38M 0.01% 533
2021
Q3
$5.15M Sell
36,237
-833
-2% -$123K 0.01% 513
2021
Q2
$5.79M Buy
37,070
+6,163
+20% +$998K 0.02% 480
2021
Q1
$4.8M Buy
30,907
+1,591
+5% +$246K 0.02% 474
2020
Q4
$4.39M Buy
29,316
+2,949
+11% +$417K 0.02% 456
2020
Q3
$3.48M Buy
26,367
+816
+3% +$107K 0.02% 456
2020
Q2
$2.96M Buy
25,551
+3,533
+16% +$407K 0.02% 481
2020
Q1
$2.16M Sell
22,018
-15,218
-41% -$1.99M 0.02% 477
2019
Q4
$5.41M Buy
37,236
+7,695
+26% +$1.06M 0.03% 441
2019
Q3
$3.94M Buy
29,541
+1,882
+7% +$243K 0.02% 462
2019
Q2
$3.16M Sell
27,659
-5,280
-16% -$618K 0.02% 496
2019
Q1
$4.08M Sell
32,939
-5,355
-14% -$609K 0.02% 455
2018
Q4
$3.86M Buy
38,294
+8,972
+31% +$1.01M 0.03% 439
2018
Q3
$3.74M Sell
29,322
-2,640
-8% -$314K 0.03% 489
2018
Q2
$3.46M Sell
31,962
-2,313
-7% -$252K 0.02% 515
2018
Q1
$3.63M Buy
34,275
+969
+3% +$113K 0.02% 505
2017
Q4
$3.9M Buy
33,306
+9,735
+41% +$1.1M 0.03% 477
2017
Q3
$2.68M Buy
23,571
+3,411
+17% +$394K 0.02% 504
2017
Q2
$2.51M Sell
20,160
-654
-3% -$77.5K 0.03% 506
2017
Q1
$2.47M Sell
20,814
-3,549
-15% -$402K 0.03% 499
2016
Q4
$2.44M Buy
24,363
+7,894
+48% +$846K 0.03% 492
2016
Q3
$2.08M Sell
16,469
-8,325
-34% -$1.03M 0.03% 478
2016
Q2
$2.9M Buy
24,794
+2,921
+13% +$331K 0.04% 368
2016
Q1
$2.26M Sell
21,873
-9,131
-29% -$883K 0.03% 421
2015
Q4
$3.09M Buy
31,004
+1,655
+6% +$162K 0.04% 387
2015
Q3
$2.68M Buy
29,349
+1,327
+5% +$133K 0.04% 396
2015
Q2
$2.97M Sell
28,022
-4,723
-14% -$523K 0.04% 389
2015
Q1
$3.74M Sell
32,745
-2,924
-8% -$334K 0.04% 376
2014
Q4
$3.93M Buy
35,669
+5,755
+19% +$607K 0.05% 376
2014
Q3
$2.92M Sell
29,914
-2,927
-9% -$288K 0.04% 512
2014
Q2
$3.31M Sell
32,841
-3,021
-8% -$295K 0.04% 458
2014
Q1
$3.29M Buy
35,862
+2,457
+7% +$226K 0.04% 450
2013
Q4
$3.02M Buy
33,405
+16,494
+98% +$1.43M 0.05% 523
2013
Q3
$1.35M Sell
16,911
-11,513
-41% -$906K 0.03% 645
2013
Q2
$2.07M Buy
+28,424
New +$2.13M 0.04% 445

Other funds holding ZBH

ProShare Advisors's ZBH Position: Q2 2026 in Review

ProShare Advisors increased its Zimmer Biomet (ZBH) stake by 21% in Q2 2026, buying an estimated $564K and bringing the position to 37,088 shares worth $3.19M. The position accounts for ﹤0.01% of the portfolio, ranked #632.

ProShare Advisors first reported a position in ZBH in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.93M in Q3 2024. 906 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.

  • ProShare Advisors held 37,088 shares of Zimmer Biomet worth $3.19M as of Q2 2026.
  • ProShare Advisors bought 6,437 Zimmer Biomet shares in Q2 2026, an estimated $564K.
  • Zimmer Biomet made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #632 holding.
  • ProShare Advisors first reported a position in Zimmer Biomet in Q2 2013 and has held it in 53 quarters since.
  • ProShare Advisors's Zimmer Biomet position peaked at $5.93M in Q3 2024.
  • 906 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.